Has Michael Monohan, DO received payments from drug or device companies?

Yes. Drug and device makers reported $7,881 in general payments to Michael Monohan, DO across 507 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michael Monohan, DO did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michael Monohan, DO come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michael Monohan, DO

Family Medicine · Post Falls, IDNPI 1942298054

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 507 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 56 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,881in general payments, 2019–2025

Across 507 payments — averaging $15.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$1K
Pfizer$1K
GSK$700
Amgen$688
Novo Nordisk$352
Bayer$267
plus $3K from 50 others

What the payments were for

Food & beverage$7,881100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	85	$1,371
Pfizer	98	$1,115
GSK	74	$700
Amgen(2 entities)	39	$688
Novo Nordisk	23	$352
Bayer	9	$267
Boehringer Ingelheim	13	$246
Novartis	11	$229
Johnson & Johnson	10	$190
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	10	$176
Exact Sciences	7	$158
Lilly USA, LLC	10	$157
AstraZeneca	9	$156
Abbott	7	$145
Takeda Pharmaceuticals U.S.A., Inc.	10	$133
Otsuka America Pharmaceutical, Inc.	6	$130
Amarin Pharma, Inc.	8	$128
Axonics, Inc.	1	$117
Corcept Therapeutics	6	$115
Merck	6	$111
Sanofi Pasteur Inc.	4	$92
Antares Pharma, Inc.	4	$70
Xeris Pharmaceuticals, Inc.	3	$66
Medtronic(2 entities)	4	$64
Boston Scientific	3	$62
Corium, LLC	2	$46
Astellas Pharma US Inc	3	$46
Dexcom, Inc.	2	$41
Genentech USA, Inc.	2	$40
Acadia Pharmaceuticals Inc	2	$39
Ironshore Pharmaceuticals Inc.	2	$38
Eisai Inc.	2	$38
Mylan Specialty L.p.	2	$36
Gilead	2	$34
Sanofi-aventis U.S. LLC	2	$34
Organon	2	$33
Alfasigma USA, Inc.	2	$31
Intercept Pharmaceuticals, Inc.	1	$29
Hologic Sales And Service, LLC	2	$28
Nevro Corp.	1	$28
Insulet Corporation	1	$25
Grifols USA, LLC	2	$24
Phathom Pharmaceuticals, Inc.	2	$24
Biohaven Pharmaceutical Holding Company Ltd.	1	$24
Edwards Lifesciences	1	$22
BD	1	$21
Daiichi Sankyo Inc.	1	$21
Halozyme Inc	1	$19
Ultragenyx Pharmaceutical Inc.	1	$19
Axsome Therapeutics, Inc.	1	$18
Teva Pharmaceuticals USA, Inc.	1	$18
Biohaven Pharmaceuticals, Inc.	1	$15
E.r. Squibb & Sons, L.L.C.	1	$15
Coopersurgical, Inc.	1	$13
Shire North American Group Inc	1	$11
Linus Health, Inc.	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Nubeqa$143
Xofigo$143
Axonics$117

How this compares

$7,881 in reported general payments places this provider in the 95th percentile of 803 family medicine providers in Idaho.

See all family medicine providers in Idaho →

Medicare billing

Part B allowed, 2024

$51,405

Medicare patients

124

Services billed

673

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OzempicSemaglutide	47	$66,192
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	37	$25,024
EliquisApixaban	27	$21,648
JardianceEmpagliflozin	18	$20,083
TrulicityDulaglutide	13	$13,317
Aimovig AutoinjectorErenumab-Aooe	12	$8,573
MyrbetriqMirabegron	16	$7,387
OxycontinOxycodone Hcl	11	$5,166
Rosuvastatin Calcium	249	$4,056
Gabapentin	93	$2,133
Colchicine	14	$1,602
Omega-3 Acid Ethyl Esters	35	$1,439
Duloxetine Hcl	36	$1,352
Levothyroxine Sodium	169	$1,265
Olmesartan Medoxomil	45	$1,098

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Novo NordiskOzempic	$352	$66,19247 claims
GSKTrelegy Ellipta	$700	$25,02437 claims
PfizerEliquis	$1,115	$21,64827 claims
Boehringer IngelheimJardiance	$246	$20,08318 claims
Lilly USA, LLCTrulicity	$157	$13,31713 claims
Astellas Pharma US IncMyrbetriq	$46	$7,38716 claims
AbbVieSynthroid	$1,371	$65317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 803 family medicine providers in Idaho.